Vaxxinity reports Q3 EPS (10c), consensus (12c)

“We continue to advance our clinical programs and to validate our platform with the goal of addressing major chronic diseases with more convenient, cost-effective, and accessible immunotherapies worldwide. This quarter, we have demonstrated proof of technology with our third clinical program, as well as our first proof of mechanism in our UB-312 program for Parkinson’s. We have observed clear target engagement with aggregated alpha-synuclein in patient CSF, indicating that UB-312-induced antibodies cross the blood-brain barrier and engage the toxic pathology of Parkinson’s disease,” said Mei Mei Hu, CEO of Vaxxinity. “Our expertise in developing active immunotherapies that break immune tolerance and generate specific, potent antibodies against self-antigens has us well positioned to achieve our next important milestones in the coming year: in addition to further analyses of data from our UB-312 trial, we are excited for initial topline results from our Phase 1 trial of VXX-401, which targets PCSK9 for hypercholesterolemia, expected in the first half of 2024, and our first potential approval with UB-612 as a COVID-19 booster in the UK and Australia.